Ironwood Pharmaceuticals (NASDAQ:IRWD) Price Target Raised to $10.00

Ironwood Pharmaceuticals (NASDAQ:IRWD) had its price target raised by Citizens Jmp from $8.00 to $10.00 in a research report sent to investors on Thursday,Benzinga reports. Citizens Jmp currently has a market outperform rating on the biotechnology company’s stock.

Several other research analysts also recently issued reports on IRWD. Craig Hallum raised Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, January 5th. Zacks Research upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 1st. Citigroup raised shares of Ironwood Pharmaceuticals from a “market perform” rating to an “outperform” rating in a report on Monday, January 5th. Weiss Ratings reiterated a “sell (d)” rating on shares of Ironwood Pharmaceuticals in a research report on Monday, December 29th. Finally, Wells Fargo & Company lifted their price objective on Ironwood Pharmaceuticals from $3.00 to $5.00 and gave the stock an “equal weight” rating in a research report on Monday, January 5th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $4.93.

Ironwood Pharmaceuticals Price Performance

Shares of NASDAQ:IRWD opened at $3.42 on Thursday. The firm has a market capitalization of $556.37 million, a price-to-earnings ratio of 26.31 and a beta of 0.17. The business’s 50 day simple moving average is $4.28 and its 200-day simple moving average is $2.83. Ironwood Pharmaceuticals has a 12 month low of $0.53 and a 12 month high of $5.78.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.03). The firm had revenue of $47.71 million for the quarter, compared to analyst estimates of $86.10 million. Ironwood Pharmaceuticals had a negative return on equity of 13.72% and a net margin of 8.11%. On average, equities analysts anticipate that Ironwood Pharmaceuticals will post 0.1 earnings per share for the current year.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

Several hedge funds have recently made changes to their positions in IRWD. ProShare Advisors LLC grew its position in shares of Ironwood Pharmaceuticals by 9.6% in the fourth quarter. ProShare Advisors LLC now owns 36,315 shares of the biotechnology company’s stock valued at $122,000 after purchasing an additional 3,170 shares during the period. Integrated Wealth Concepts LLC boosted its stake in Ironwood Pharmaceuticals by 21.4% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 19,295 shares of the biotechnology company’s stock worth $25,000 after buying an additional 3,406 shares during the last quarter. Mercer Global Advisors Inc. ADV boosted its stake in Ironwood Pharmaceuticals by 7.8% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 76,951 shares of the biotechnology company’s stock worth $259,000 after buying an additional 5,598 shares during the last quarter. Public Employees Retirement System of Ohio grew its holdings in Ironwood Pharmaceuticals by 11.7% in the 4th quarter. Public Employees Retirement System of Ohio now owns 67,888 shares of the biotechnology company’s stock valued at $229,000 after buying an additional 7,120 shares during the period. Finally, Merit Financial Group LLC increased its stake in shares of Ironwood Pharmaceuticals by 17.4% during the 3rd quarter. Merit Financial Group LLC now owns 48,879 shares of the biotechnology company’s stock valued at $64,000 after acquiring an additional 7,232 shares during the last quarter.

More Ironwood Pharmaceuticals News

Here are the key news stories impacting Ironwood Pharmaceuticals this week:

• Positive Sentiment: Analyst price-target lift from Citizens JMP — Citizens JMP raised its price target to $10 and kept a “market outperform” rating, signaling significant upside potential if execution or pipeline news turns favorable. Read More.
• Neutral Sentiment: Q4 earnings call highlighted continued strength in LINZESS sales even as overall revenue fell; investors will watch whether LINZESS can stabilize top-line trends going forward. Read More.
• Neutral Sentiment: Post-quarter valuation and 2026 revenue guidance analysis is prompting re‑rating discussions — analysts and commentators are reworking models after the miss, which could amplify volatility while estimates are adjusted. Read More.
• Neutral Sentiment: Market commentaries explaining the share drop (e.g., coverage pieces) are framing the move as a reaction to the earnings miss plus guidance/pipeline uncertainty rather than a single catalyst. Read More.
• Negative Sentiment: Pipeline setback for apraglutide and an extended development timeline — Seeking Alpha and other analysts lowered expectations after management pushed timelines, increasing risk to future upside from the pipeline. Read More.
• Negative Sentiment: Q4 results missed estimates — IRWD reported a loss for the quarter, with revenue falling ~47% YoY and coming in well below consensus, which directly triggered the share sell-off. Read More.
• Negative Sentiment: Zacks Research downgraded IRWD from “strong-buy” to “hold,” removing a supportive endorsement and adding selling pressure amid the disappointing quarter. Read More.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.